Improving Bladder Function in SCI by Neuromodulation

February 10, 2026 updated by: Daniel Lu, MD, PhD, University of California, Los Angeles
This trial will investigate the safety and utility of spinal cord neuromodulation to improve urinary bladder function in the context of spinal cord injury.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This trial will investigate the safety and utility of spinal cord neuromodulation to improve urinary bladder function in the context of spinal cord injury. Neuromodulation will be in the form of transcutaneous electrical stimulation and/or magnetic stimulation.

Study Type

Interventional

Enrollment (Estimated)

24

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United States
    • California
      • Los Angeles, California, United States, 90095
        • Recruiting
        • University of California, Los Angeles
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 45 years (Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Male 18-45 years;
  2. At least 1 year post-injury;
  3. Non-progressive SCI at C2-T8 (non-conus injury);
  4. Motor Complete ASIA (A or B);
  5. Neurogenic bladder requiring clean intermittent straight catheterization;
  6. Able to attend twice weekly testing sessions for 6 months.
  7. Have intact lower extremity anatomy and able to use lower extremity for assistive standing and stepping.

Exclusion Criteria:

  1. History of autonomic dysreflexia;
  2. Ventilator dependency;
  3. Musculoskeletal dysfunction, unhealed fracture, pressure ulcer, active infection;
  4. Clinically significant depression or ongoing drug abuse;
  5. Received botox injection, or bladder surgery (suprapubic access, Brindley procedure, etc.); 6. Prostatic hypertrophy or bladder outlet disorder;

7. Cardiopulmonary disease that precludes lower extremity training or rehabilitation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Stimulation of Non-Naive
Evaluate neuromodulation in 6 subjects with prior motor training.
Device: Electromagnetic Neuromodulation
Electromagnetic stimulation to neuromodulate the spinal cord in the context of spinal cord injury.
Other Names:
  • Transcutaneous Electrical Stimulation
  • Magnetic Stimulation
Experimental: Stimulation of Naive
Evaluate neuromodulation in 6 naive subjects.
Device: Electromagnetic Neuromodulation
Electromagnetic stimulation to neuromodulate the spinal cord in the context of spinal cord injury.
Other Names:
  • Transcutaneous Electrical Stimulation
  • Magnetic Stimulation
Experimental: Stimulation
Apply parameters discovered in Arm 1 and Arm 2 to evaluate neuromodulation in 12 naive subjects.
Device: Electromagnetic Neuromodulation
Electromagnetic stimulation to neuromodulate the spinal cord in the context of spinal cord injury.
Other Names:
  • Transcutaneous Electrical Stimulation
  • Magnetic Stimulation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Urine flow and volume
Time Frame: Months 1-48
Months 1-48

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of California, Los Angeles

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2015

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

January 31, 2027

Study Registration Dates

First Submitted

January 3, 2015

First Submitted That Met QC Criteria

January 3, 2015

First Posted (Estimated)

January 6, 2015

Study Record Updates

Last Update Posted (Actual)

February 13, 2026

Last Update Submitted That Met QC Criteria

February 10, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 14-000932

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe